Sentence examples for markers in plasma from inspiring English sources

We now demonstrate that there is an abundant release of NET-related markers in plasma from melioidosis patients.

We hypothesized that biological markers in plasma can rule out VAP at the moment of clinical suspicion and could rule in VAP before the diagnosis can be made clinically.

We hypothesized that biological markers in plasma, other than CRP and PCT, can add to the diagnostic process of VAP in two distinct ways; first, they could rule out VAP at the moment of clinical suspicion; second, they could rule in VAP before the diagnosis can be made clinically.

All of the measured mediators in plasma except for IL-18 and TNFα gave statistically significant results in ROC curve analysis (Table 4). Figure 2a c show the three most significant ROC curves of individual markers in plasma (NO x, IL-6, uric acid).

Thus, there was a significantly higher frequency of methylated markers in plasma of patients with polyps versus healthy controls (p = 0.0068).

Moreover, our unfavorable markers in plasma showed differences between lymphoma subtypes: they were more characteristic of B-cell tumors with high proliferation.

Our primary analysis compares the performance of the marker in plasma from patients with colorectal cancer vs. the subjects without colorectal disease.

Blood samples were also collected from non-pregnant individuals as negative controls for validating the fetal-specificity of the candidate marker in plasma.

First, we determined the presence of a single DNA methylation marker in plasma from patients with colorectal precancerous lesions, CRC, in healthy controls without any colorectal pathology, patients with chronic inflammation, or other gastrointestinal diseases and patients with a high risk for CRC due to family history or positive FOBT (Table 2).

Although in our study we measured these bio-markers in plasma, which may not parallel intracellular levels, their increase after supplementation reflects greater protection against oxidative stress.

Treatment responses of recurrent glioblastoma patients (n = 26) treated with the VEGF and PlGF sequestering drug aflibercept were not associated with significant changes in plasma protein levels of VEGF, despite initial reduction of this marker in plasma and subsequent increases of circulating VEGF and PlGF after 2 weeks of treatment [ 62].